Pioneering Antibody Scaffold Engineering
Innovators of Peptide Drugs
We Are Visionaries
At AdaptBio, we perform cutting edge basic and translational research enabling medical innovation to fulfil our core value of patient-centered innovation. We exploit our ADAPT platform technology to create novel peptide drugs, inhibitors of challenging protein-protein interactions in therapeutic areas of high unmet medical need.
Our mission is to create peptide-based medicines that transform the lives of patients by accelerating the discovery of new therapeutic modalities inspired by high-affinity antibody drugs.
1
Antibody CDR-H3 Mimics
--
IMMUNO-ONCOLOGY Breakthrough
RESEARCH PROJECTS with MD ANDERSON and the VA-MIAMI
CDR-H3 ADAPTin blockers of the PD1/PDL1 immune checkpoint involved in cancer immune evasion are being developed based on FDA-approved Pembrolizumab and Durvalumab antibodies. Our preclinical lead candidates are being tested on spheroid PDOT models from Melanoma and NSCLC patients.
2
Next-Gen Peptide Vaccines
--
Tuning Patients' Immune System
RESEARCH PROJECTS in COLLABORATION with INDIANA UNIVERSITY
Our ADAPT technology offers an unprecedented approach to engineering Hairpin Constrained Epitopes into novel chimeric peptide vaccines. These peptide vaccines developed in collaboration with Prof. Pravin Kaumaya stimulate a sustained humoral and cellular immunity induced by B- and T-cell responses, inhibiting tumor growth in several syngeneic mouse models. We are excited to start a second phase of vaccine optimization creating bispecific models of vaccines targeting HER2/HER3 and VEGF/PD1 for combination purposes.
3
Drug Discovery & Delivery
--
Smaller, Faster, Deeper
RESEARCH PROJECT with DMPK lab at the UF-SCRIPPS Research Institute
We work hand-in-hand with DMPK labs to develop this new ADAPTin therapeutic modality into lead candidates with drug-like properties: higher affinity, solubility, stability, longer half-life, longer systemic circulation, and stronger tissue and cellular penetration. These efforts drive the discovery of novel ADAPTin peptide drugs, inhibitors of challenging protein-protein interactions (PPIs) in therapeutic areas of high unmet medical need.
"Our next goal is to demonstrate the disruptive nature of our platform technology, because we have a new tool on hand to streamline the synthesis of peptide therapeutics never seen before." Stéphane Roche
ADAPTins (yellow) are CDR-H3 Peptides that bound and Block access to the surface of misregulated or Toxic Proteins.
Stéphane Roche
Founder and CEO of AdaptBio
Join Our Team
We’re looking for highly-motivated and talented people to join our innovative team.
Submit your application today to join the AdaptBio journey!
OUR TEAM
Stéphane Roche
Founder/CEO
Stéphane is the founder and CEO of AdaptBio Therapeutics (Est. in 2024). He has over 15 years of experience in synthetic and medicinal chemistry in diverse therapeutic areas working on small-molecule natural products and peptide drugs. This rich experience in drug discovery drives his interest in solving complex issues at the interface of science, medicine, and business strategy to create novel medicines that will improve the lives of patients and their families.
Ivan Jozic
Chief Operating Officer
Ivan has over 10 years of experience in cutaneous physiology and pathophysiology, as well as biomarker development and targeted therapies for treatment of cutaneous diseases. He is also an Editorial Board Member at Frontiers in Medicine (Dermatology). In his role of COO, Ivan leads the clinical development of the company’s portfolio in dermatology, immunology, and vaccine therapeutics, as well as establishing AdaptBio as a trusted partner to the Immuno-Oncology community.
George Theodore
Chief Business Officer
George has been involved in biomedical research for over 15 years as a medical research consultant. His expertise in molecular medicine led him to write clinical and translational research projects for the US Dept. of Health, Abbott, BMS, AstraZeneca, Roche/Genentech, and Janssen. George joined AdaptBio in 2024 to lead our commercial development and corporate strategy.
Tracy Vuong
Chief Financial Officer
Tracy has over 15 years of experience in sponsored research administration at multiple universities, including a Carnegie-classified R1 institution. His expertise focuses on contract negotiation and award management, including strong knowledge of State and Federal regulations (2 CFR Part 200 and FAR/DFAR). Tracy provides grant management and accounting leadership to optimize our business development strategy's financial and commercial goals.
Current technology success rate
> 80% of scaffolds tested are Functional
Entering a New Era of Modular Drug Design
Our ADAPT platform allows us to engineer a wide range of Antibody CDR-H3 scaffolds, precise peptide mimics with 3-D shapes adaptable to targets typically considered “undruggable”.
Novel Therapeutic Space
Our ADAPT platform allows us to engineer a wide range of Antibody CDR-H3 scaffolds, precise peptide mimics with 3-D shapes adaptable to targets typically considered “undruggable”.
